Asset
LONCASTUXIMAB TESIRINE
ADC THERAPEUTICS SA COMMON SHARES
Revenue
No revenue reported in loaded filings.
Clinical trials (11)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05144009 | phase2 | terminated | 2022-06-21 | 2024-01-22 | ADC Therapeutics S.A. | A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL) |
| NCT05660395 | phase1 | terminated | 2023-07-28 | 2026-06-25 | ADC Therapeutics S.A. | A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10) |
| NCT04970901 | phase1 | active_not_recruiting | 2022-06-17 | 2027-03-31 | ADC Therapeutics S.A. | A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) |
| NCT04974996 | phase1 | withdrawn | 2022-02-01 | 2024-03-11 | ADC Therapeutics S.A. | A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8) |
| NCT03685344 | phase1 | terminated | 2019-02-04 | 2020-10-27 | ADC Therapeutics S.A. | Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma |
FDA applications (0)
This company has no applications containing this asset.